Drugs / EV68-228-N
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06444048 | Jun 2024 → Apr 2025 | enterovirus infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EV68-228-N | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06444048 ↗ |
| Modality | Monoclonal antibody | “EV68-228-N is a recombinant human monoclonal IgG1 antibody” NCT06444048 ↗ |
| Route | Intravenous | “single intravenous dose of EV68-228-N” NCT06444048 ↗ |